Thermo Fisher Expands U.S. Cell And Gene Therapy Network With New Philadelphia ATxCC

Thermo Fisher Scientific has officially opened its East Coast flagship Advanced Therapies Collaboration Center (ATxCC) in Philadelphia, expanding its nationwide network dedicated to supporting cell and gene therapy (CGT) development. This marks the company’s second U.S. ATxCC, following its Carlsbad, California facility, and further strengthens Thermo Fisher’s infrastructure for driving innovation in next-generation cell-based immunotherapies across biotech, biopharma, and research communities.

“Our new Advanced Therapies Collaboration Center in Philadelphia is designed to help innovators overcome critical hurdles in developing cell and gene therapies,” said Nicole Brockway, president, biosciences, Thermo Fisher Scientific. “This center will play a key role in supporting customers as they progress from the lab to the clinic and, most importantly, bring transformative therapies to patients faster.”

The new Philadelphia site features integrated laboratory and collaborative spaces designed to facilitate the transition of advanced therapies from early discovery to clinical readiness for researchers. As the CGT field rapidly evolves—promising transformative options for diseases once deemed untreatable—the need for scalable technical support and specialized process development continues to rise. Thermo Fisher’s investment underscores its commitment to enabling the fast-growing advanced therapies ecosystem.

"We’re proud to expand our network-wide partnership with Thermo Fisher Scientific through this unique offering. By embedding the ATxCC within the BioLabs community, we are creating a uniquely rich and accessible resource for founders and startup teams working on groundbreaking therapies in Philadelphia,” said Johannes Fruehauf, PhD, MD, Founder and CEO of BioLabs, the premier global network of life science incubators. “It will offer game-changing access to high-end technologies not only for our BioLabs members but also to external high-potential biotechs from across the East Coast and internationally.”

Situated inside the newly expanded 53,000-square-foot BioLabs for Advanced Therapeutics Philadelphia incubator, the ATxCC provides emerging startups and established biopharma companies with direct access to Thermo Fisher’s scientific expertise, cutting-edge process development tools, and strategic collaboration opportunities. The facility aims to empower innovators with the resources needed to accelerate the advancement of life-changing therapies.